Josh Cohen co-founded Amylyx Pharmaceuticals (NASDAQ: AMLX) in 2013 and continues to serve as its co-CEO. Josh, alongside co-CEO Justin Klee, has overseen the growth of Amylyx -- from its start as a concept dreamed up in a dorm room through its IPO, FDA and Health Canada approvals of its first product, and product launch -- to the company it is today, with a mission to usher in a new era for treating diseases with high unmet needs.
Josh co-invented the oral, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO, also known as ursodoxicoltaurine), which is being explored for the potential treatment of neurodegenerative diseases. Amylyx’ clinical trial results in collaboration with leading experts have been published in several peer-reviewed medical journals, including the New England Journal of Medicine, Muscle & Nerve, and the Journal of Neurology, Neurosurgery and Psychiatry.
In 2020, Josh and Justin were named to Business Insider’s 30 Under 40 in Healthcare list and PM360’s ELITE in the Drug Researchers and Developers category. Amylyx was also selected as one of Fierce Biotech’s 2020 Fierce 15 companies. Josh and Justin were named to PM360’s 2022 ELITE Entrepreneurs list, were awarded the Harvey and Bonny Gaffen Advancements in ALS Award by the Les Turner Foundation in 2022, and received the Henri Termeer Transatlantic Connections Award the same year. The CENTAUR clinical trial team made up of Amylyx, the MGH Neurological Clinical Research Institute, the Northeast ALS Consortium, and Barrow Neurological Institute was also awarded the 2022 Annual Healey Center International Prize for Innovation in ALS, an award that recognizes excellence in research for an individual or team who catalyze exceptional discoveries leading to a transformative therapy development in ALS. Josh and Justin were also awarded the Northeast ALS Consortium (NEALS) Big Data Award in 2022 for their application of real world evidence approaches in ALS clinical research.
Stemming from his background in biomedical engineering, Josh is passionate about improving outcomes where there is a significant unmet need by pursuing research into novel drug candidates as a part of Amylyx’ ongoing commitment to end the suffering caused by neurodegenerative diseases. Josh was a National Merit Scholar and earned his Bachelor of Science in biomedical engineering from Brown University. While attending Brown, Josh founded the Brown Biotechnology Investment Group and published research at the National Institutes of Standards and Technology (NIST) and in the Journal of Pharmaceutical Sciences.
What is Joshua B. Cohen's net worth?
The estimated net worth of Joshua B. Cohen is at least $101.12 million as of January 15th, 2026. Cohen owns 3,378,621 shares of Amylyx Pharmaceuticals stock worth more than $101,122,127 as of September 24th. This net worth approximation does not reflect any other investments that Cohen may own. Learn More about Joshua B. Cohen's net worth.
How do I contact Joshua B. Cohen?
Has Joshua B. Cohen been buying or selling shares of Amylyx Pharmaceuticals?
Joshua B. Cohen has not been actively trading shares of Amylyx Pharmaceuticals over the course of the past ninety days. Most recently, Joshua B. Cohen sold 1,974 shares of the business's stock in a transaction on Friday, January 16th. The shares were sold at an average price of $13.83, for a transaction totalling $27,300.42. Following the completion of the sale, the chief executive officer now directly owns 3,379,465 shares of the company's stock, valued at $46,738,000.95. Learn More on Joshua B. Cohen's trading history.
Who are Amylyx Pharmaceuticals' active insiders?
Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), Karen Firestone (Director), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amylyx Pharmaceuticals?
In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 8,100 shares worth more than $100,845.00. In the last year, insiders at the sold shares 15 times. They sold a total of 294,490 shares worth more than $4,701,360.02. The most recent insider tranaction occured on September, 10th when insider
Camille L Bedrosian sold 10,028 shares worth more than $324,907.20. Insiders at Amylyx Pharmaceuticals own 10.9% of the company.
Learn More about insider trades at Amylyx Pharmaceuticals. Information on this page was last updated on 9/10/2026.
